Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 15 de 15
Filter
1.
Appl Immunohistochem Mol Morphol ; 30(7): 509-516, 2022 08 01.
Article in English | MEDLINE | ID: mdl-35777983

ABSTRACT

Luteinizing hormone-releasing hormone receptor (LHRHR) expression has been reported in various cancers, including endometrial neoplasms. Thus, LHRHR provides a potential point for therapeutic approach using LHRH analogs as carrier molecules for chemotherapeutic agents in this cancer population. However, clinical data did not prove any potential benefits for patients. We decided to assess LHRHR expression in patients with endometrial cancer to explain possible lack of efficacy in previous clinical reports. LHRHR expression was assessed immunohistochemically in different anatomic and histogenetic compartments of female genital tract of patients with endometrial cancer. The study sample consisted of paraffin tissue blocks obtained from patients who has undergone primary surgery owing to endometrial cancer. Strong LHRHR expression was found in endometrial cancer, fallopian tube, and concurrent atypical hyperplasia. Interestingly, LHRHR expression showed significant differences depending on the respective compartment of the ovary analyzed. Level of LHRHR expression in patients with primary advanced and unresectable disease, particularly in certain ovarian compartments may be substantially lower, which may influence the use of new targeted therapy regimens. The studies on secondary Müllerian system compartment and its hormonal receptor status may be crucial to understand mechanisms of lack of efficacy of LHRH hybrid molecules anti-cancer treatment.


Subject(s)
Antineoplastic Agents , Endometrial Neoplasms , Antineoplastic Agents/therapeutic use , Endometrial Neoplasms/metabolism , Female , Genitalia, Female/metabolism , Gonadotropin-Releasing Hormone/metabolism , Gonadotropin-Releasing Hormone/therapeutic use , Humans , Receptors, LHRH/metabolism , Receptors, LHRH/therapeutic use
2.
Oncol Rep ; 32(6): 2349-53, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25231141

ABSTRACT

Endometrial cancer (EC) is one of the most common gynecological malignancies in Poland, with well-established risk factors. Genetic instability and molecular alterations responsible for endometrial carcinogenesis have been systematically investigated. The aim of the present study was to investigate, by means of cDNA macroarrays, the expression profiles of genes encoding extracellular matrix (ECM) proteins in ECs. Tissue specimens were collected during surgical procedures from 40 patients with EC, and control tissue was collected from 9 patients with uterine leiomyomas. RNA was isolated and RT-PCR with radioisotope-labeled cDNA was performed. The levels of ECM protein gene expression in normal endometrial tissues were compared to the expression of these genes in EC specimens. Statistically significant differences in gene expression, stratified by clinical stage of the ECs, were detected for aggrecan, vitronectin, tenascin R, nidogen and two collagen proteins: type VIII chain α1 and type XI chain α2. All of these proteins were overexpressed in stage III endometrial carcinomas compared to levels in stage I and II uterine neoplasms. In conclusion, increased expression of genes encoding ECM proteins may play an important role in facilitating accelerated disease progression of human ECs.


Subject(s)
Endometrial Neoplasms/metabolism , Extracellular Matrix Proteins/metabolism , Adult , Aged , Endometrial Neoplasms/pathology , Extracellular Matrix Proteins/genetics , Female , Humans , Middle Aged , Neoplasm Staging , Transcriptome
3.
Prz Gastroenterol ; 9(1): 57-61, 2014.
Article in English | MEDLINE | ID: mdl-24868301

ABSTRACT

Amyloidosis is characterised by the accumulation of poorly soluble fibrous proteins in the extracellular space of various bodily organs. Light chain amyloidosis (AL) is recognised as the most common form of systemic amyloidosis. Light chains are deposited in the majority of bodily organs, and accumulation of them in the liver produces hepatomegaly. We report a case of AL-systemic amyloidosis with liver involvement in a 71-year-old woman. Hepatomegaly, weight loss and general malaise were the first manifestations of the disease. Liver biopsy found amyloid deposits along the sinusoids as well as in the space of Disse, inside the vascular wall and in connective tissue of the portal tracts, which showed a positive reaction in Congo Red stain. Further diagnosis showed the presence of systemic amyloidosis. The patient was put on cyclophosphamide and steroid therapy.

4.
Pneumonol Alergol Pol ; 80(3): 269-74, 2012.
Article in Polish | MEDLINE | ID: mdl-22562277

ABSTRACT

Malignant peripheral nerve sheath tumor (MPNST) is a rare malignant counterpart to benign neurogenes tumors such as schwannomas and neurofibromas and account for approximately 5-10 % of all soft tissue sarcomas. This neoplasm is also referred to older designations as a malignant schwannoma, malignant neurilemmoma or neurogenic sarcoma. A patient was a woman of 59 years old with a diagnosed malignant neurilemmoma, treated since 1993. Operated several times and subjected to radiotherapy due to the local recurrence of the tumors located in the soft tissues of the back until 2002; Treated with chemotherapy (doxorubicin) and operated due to a lung metastases. The therapy resulted in a total remission that lasted 12 months. In 2004 a new small tumor was diagnosed in the right lung, which had been followed up until 2006. The patient did not give permission to a second surgery, treated with ifosfamide. In 2006 she was operated for renal cell carcinoma of the left kidney. In 2009, due to a following progression of neurilemmoma and a worsening overall condition, she was subsequently treated with a combination of gemcitabine and docetaxel. The treatment resulted in a slight improvement, but was stopped due to complications (pancytopenia). In 2010 another progression of the disease occurred, which resulted in pleural metastases and osteolytic lesions in the vertebrae (Th6 and L2).


Subject(s)
Carcinoma, Renal Cell/secondary , Carcinoma, Renal Cell/surgery , Kidney Neoplasms/surgery , Neoplasms, Second Primary/secondary , Neoplasms, Second Primary/surgery , Nerve Sheath Neoplasms/therapy , Neurilemmoma/therapy , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Bone Neoplasms/secondary , Chemoradiotherapy, Adjuvant , Disease Progression , Female , Humans , Lumbar Vertebrae , Lung Neoplasms/secondary , Lung Neoplasms/therapy , Middle Aged , Neoplasm Recurrence, Local/therapy , Pleural Neoplasms/secondary , Spinal Neoplasms/secondary , Thoracic Vertebrae
5.
Oncol Rep ; 26(1): 153-60, 2011 Jul.
Article in English | MEDLINE | ID: mdl-21491087

ABSTRACT

Human papillomavirus (HPV) is widely accepted as the main cause of cervical cancer. However, the presence of HPV DNA does not inescapably lead to the development of the cancerous phenotype of the infected cell. Therefore, it is considered that the induction of full cancerous expression of HPV requires additional cofactors. The aim of this study was to assess the expression of estrogen receptor α (ERα) and progesterone receptor (PR) in archived tissue blocks of squamous cell carcinoma and adenocarcinoma of the uterine cervix and to ascertain whether expression of these receptors is associated with the presence of HPV DNA. The investigation was performed using formalin-fixed, paraffin-embedded cervical cancer specimens obtained from 250 women who underwent surgery for histologically confirmed neoplastic lesions. The control group consisted of normal cervical tissues obtained from 50 patients who underwent myomectomy. The results of this study revealed that the expression of ER and PR in planoepithelial cancers and adenocarcinomas of the cervix were decreased to undetectable levels. Only in singular cases in the pattern of staining the expression of ER and PR was noted. In stromal cells of the tested neoplasms, higher expression of both types of receptors was found. Comparison of the expression of ER and PR in the staining pattern and stroma of both squamous cell carcinoma and adenocarcioma of the cervix, showed statistically higher expression in the stromal cells. Strong expression (+1, +2, +3) of ER and PR was noted in the stromal cells irrespective of HPV infection, histopathological type of cancer, and clinical and histopathological grade.


Subject(s)
Alphapapillomavirus/metabolism , Gene Expression Regulation, Viral , Papillomavirus Infections/complications , Receptors, Estrogen/biosynthesis , Receptors, Progesterone/biosynthesis , Uterine Cervical Neoplasms/metabolism , Adenocarcinoma/metabolism , Adenocarcinoma/virology , Carcinoma, Squamous Cell/metabolism , Carcinoma, Squamous Cell/virology , Cervix Uteri/metabolism , DNA, Viral , Female , Humans , Immunohistochemistry/methods , Neoplasm Invasiveness , Papillomavirus Infections/virology , Polymerase Chain Reaction/methods , Uterine Cervical Neoplasms/virology
6.
Arch Med Sci ; 6(1): 65-70, 2010 Mar 01.
Article in English | MEDLINE | ID: mdl-22371722

ABSTRACT

INTRODUCTION: The aim of this study was to investigate the prognostic significance of proliferating cell nuclear antigen (PCNA) expression in laryngeal carcinoma in relation to clinicopathological features. Special emphasis was placed on examining the relationship of PCNA expression in the primary tumour and PCNA expression in corresponding lymph node metastases obtained from the same patients. MATERIAL AND METHODS: The study included 60 patients with advanced larynx carcinoma who had received treatment and follow-up for at least 5 years. Sixty laryngeal carcinoma specimens and metastatic lymph nodes from 24 patients were examined for immunohistochemical PCNA expression. RESULTS: The percentages of PCNA positive cells were significantly higher in the primary tumours which developed lymph node metastases than in those without metastases. The fraction of PCNA immunolabelled cells in metastatic lymph nodes increased significantly when compared with the PCNA positive cell score in their corresponding primary tumours obtained from the same patient. There was a significant difference in PCNA index score in primary tumours between the group of patients who survived a 5-year period and those who died within 5 years after treatment. CONCLUSIONS: Our data demonstrate that a high proliferation index in primary larynx tumours is retained and increased in corresponding lymph node metastases. Measurement of the fraction of cancer cells stained for PCNA in primary larynx carcinomas can be helpful in selecting tumours with high aggressiveness potential that are more likely to develop neck metastases and thereby in identifying patients who need elective lymph node dissection or additional treatment.

7.
Ann Thorac Surg ; 88(4): e39-41, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19766776

ABSTRACT

Myelolipoma is a rare neoplasm composed of an admixture of mature adipose tissue and hematopoietic elements. It typically occurs in adrenal glands as a solitary, well-circumscribed mass, and the thoracic location is extremely unusual. We present a 63-year-old man with an accidentally detected tumor of the chest wall. Thoracoscopic resection and subsequent histopathologic examination of the lesion revealed myelolipoma with bony spicules, which are an unusual component in this neoplasm. We discuss the etiology, histopathology, differential diagnosis, and recommended management of extra-adrenal myelolipoma, and we conclude that it should be considered in the differential diagnosis of subpleural chest wall tumors.


Subject(s)
Lung Neoplasms/diagnosis , Myelolipoma/diagnosis , Pneumonectomy/methods , Diagnosis, Differential , Follow-Up Studies , Humans , Lung Neoplasms/surgery , Male , Middle Aged , Myelolipoma/surgery , Thoracoscopy , Tomography, X-Ray Computed
8.
Ginekol Pol ; 80(12): 907-13, 2009 Dec.
Article in Polish | MEDLINE | ID: mdl-20120935

ABSTRACT

OBJECTIVES: The aim of this study was to investigate, by means of cDNA macroarrays, the expression profile of genes coding the ECM proteins in endometrial cancer. MATERIAL AND METHODS: Tissue specimens were collected during surgical procedures. 40 patients were operated due to endometrial cancer and 9 patients because of uterine myomas. RNA was isolated and reverse transcriptase reaction with radioisotope labeling of cDNA were performed. PCR reaction was performed with labeled cDNA. All steps of macroarray hybridization were done according to the protocol. Statistical analysis was done with different tests, including artificial neural network method. RESULTS: The level of ECM protein genes expression in normal endometrial tissue was compared to the expression of these genes in endometrial cancer specimens. Statistical significances were found only for fibronectin and osteonectin genes and for both genes decreased expression was observed in cancer tissues (p = 0.009, p = 0.0003, respectively). Moreover fibronectin and osteonectin genes expression decreased along with increase of clinical staging and histological grading of the endometrial cancer but no statistical significance for this trend was found. CONCLUSIONS: Decreased expression of fibronectin and osteonectin genes, when compared to normal endometrial tissue expression, in endometrial cancer may play an important role as a stimulus for disease development and, on the other hand, may be used as an additional marker for the progression of the disease.


Subject(s)
Biomarkers, Tumor/genetics , Endometrial Neoplasms/genetics , Fibronectins/genetics , Gene Expression Regulation, Neoplastic/genetics , Osteonectin/genetics , Endometrial Neoplasms/metabolism , Endometrial Neoplasms/pathology , Female , Humans , Poland , Prognosis , RNA, Messenger/genetics , Reverse Transcriptase Polymerase Chain Reaction/methods
9.
Lung Cancer ; 51(1): 61-9, 2006 Jan.
Article in English | MEDLINE | ID: mdl-16297499

ABSTRACT

The aim of our study was to estimate the expression of the Bcl-xL gene, a member of Bcl-2 family, in NSCLC patients. A total of 60 consecutive patients diagnosed with NSCLC that underwent chemotherapy prior to surgery were reviewed. Bcl-xL expression was assessed on paraffin sections by in situ hybridization (ISH) and immunohistochemistry (IMH). We observed the presence of mRNA of Bcl-xL gene and its protein product overexpression in most patients (60 and 81.7%, respectively). In material examined no significant correlation was observed between the pattern of Bcl-xL or protein expression and any clinicopathological factors evaluated. The expression of Bcl-xL protein was low (less than 10% positive cells) in 11 patients (median survival time 29 months) as compared to 49 patients with overexpression (median survival time 21.0 months). The difference was not of statistic significance (p=0.27). In examined group the Bcl-xL mRNA was found in 36 patients, while it was absent in 24 cases. Median survival time was 14.5 and 86.5 months, respectively (p=0.001). In addition, 19.4% of 5-year survivals were achieved in patients with overexpression and 54.2% in patients with no mRNA present (p=0.002). The percentage of 5-year survival in patients with protein expression assessed by IMH was 30.6% (p=0.31). The estimation of Bcl-xL expression on mRNA and protein level was compared by the means of sign test and the significant difference was found (p=0.009). The inconsistency was related to 35% of cases. In comparison with IMH, ISH technique appeared to be more specific and accurate in assessment of 5-year survival (25 and 65%; 65 and 70%, respectively). The results of our study indicate that Bcl-xL mRNA overexpression may suggest poor prognosis in NSCLC.


Subject(s)
Carcinoma, Non-Small-Cell Lung/metabolism , Gene Expression Regulation, Neoplastic , Lung Neoplasms/metabolism , RNA, Neoplasm/genetics , bcl-X Protein/genetics , Adult , Aged , Carcinoma, Non-Small-Cell Lung/genetics , Carcinoma, Non-Small-Cell Lung/pathology , Female , Humans , Immunohistochemistry , In Situ Hybridization , Lung Neoplasms/genetics , Lung Neoplasms/pathology , Male , Middle Aged , Prognosis , Retrospective Studies , bcl-X Protein/metabolism
10.
Int J Mol Med ; 15(6): 955-61, 2005 Jun.
Article in English | MEDLINE | ID: mdl-15870899

ABSTRACT

The immunohistochemical (IHC) detection of MMR proteins is an accurate and rapid method to predict the presence of defective DNA MMR genes. MMR protein expression could also serve as a prognostic indicator of human cancers. The results of many studies demonstrate the usefulness of IHC tests with monoclonal antibodies MSH2 and MLH1 in screening the microsatellite sequence instability within both spontaneous and hereditary malignant neoplasms. The aim of our study was to perform an IHC estimation of the hMLH1 and hMSH2 expression in a subset of vulvar carcinomas according to HPV 16/18 status. The level of MMR proteins was further analyzed in relation to histoclinical features of the disease in either HPV-positive or -negative cancers. We identified archival diagnostic phase tissue specimens from 46 cases of vulvar cancer. From the same paraffin blocks containing material from the margin of surgical section during vulvectomy, normal epithelial tissue fragments were collected and designated as the control group. The characteristic of the lesion was examined in comparison with the presence of HPV DNA. Identification of the HPV 16/18 types was performed using PCR. IgG1 monoclonal antibodies detecting those epitopes characteristic for hMLH1 and hMSH2 were used in the study. In the analyzed cases of vulvar cancer, we have observed increased expression of proteins of both hMSH2 and hMLH1 genes compared to the control group. A comparison of the hMLH1 and hMSH2 protein expression levels showed that hMSH2 expression was higher than that of hMLH1 in the case of vulvar carcinomas. The performed analysis of correlation between individual parameters did not reveal statistically significant relationship with both the gradient and status of HPV 16/18. hMSH2 and hMLH1 were definitely interrelated.


Subject(s)
Carcinoma/metabolism , DNA-Binding Proteins/metabolism , Immunohistochemistry , Neoplasm Proteins/metabolism , Nuclear Proteins/metabolism , Proto-Oncogene Proteins/metabolism , Vulvar Neoplasms/metabolism , Adaptor Proteins, Signal Transducing , Adult , Aged , Aged, 80 and over , Antibodies, Monoclonal/metabolism , Carcinoma/genetics , Carcinoma/pathology , Carrier Proteins , DNA, Viral/genetics , DNA, Viral/isolation & purification , Epitopes , Female , Gene Expression , Humans , Middle Aged , MutL Protein Homolog 1 , MutS Homolog 2 Protein , Papillomaviridae/classification , Papillomaviridae/genetics , Papillomavirus Infections/genetics , Poland , Polymerase Chain Reaction , Retrospective Studies , Vulvar Neoplasms/genetics , Vulvar Neoplasms/pathology
11.
Wiad Lek ; 57(7-8): 388-91, 2004.
Article in Polish | MEDLINE | ID: mdl-15631199

ABSTRACT

The secondary neoplasms due to previous radiotherapy occur rarely. They develop within the radiation field or on its border. In this paper we present the case of soft tissue sarcoma that evolved 11 years after uterine cervix cancer radiotherapy. The long-term survival of patients subjected to radiotherapy is linked with the risk of secondary neoplasms appearance. That is why the repeated regular observation after radical treatment is recommended.


Subject(s)
Neoplasms, Radiation-Induced/etiology , Neoplasms, Second Primary/etiology , Sarcoma/etiology , Uterine Cervical Neoplasms/radiotherapy , Abdominal Neoplasms/etiology , Carcinoma, Squamous Cell/radiotherapy , Female , Humans , Middle Aged , Neoplasms, Radiation-Induced/pathology , Neoplasms, Second Primary/pathology , Prognosis , Radiotherapy Dosage , Radiotherapy, Adjuvant/adverse effects , Sarcoma/pathology
12.
Article in English | MEDLINE | ID: mdl-15314971

ABSTRACT

Cell neoplastic transformation results from disturbances in expression of genes regulating its basic functions like cell cycle and apoptosis. Our paper presents preliminary estimation of expression of protooncogenes: bcl-2 and bcl-X(L) as well as of p53 suppressor gene in (NSCLC) non-small-cell lung cancer patients. The study comprised 16 NSCLC patients subjected to chemotherapy before operative procedure. Gene expression was evaluated on paraffin embedded specimens using in situ hybridization assay and immunohistochemical method. In the majority of examined patients, high expression of bcl-X(L) gene both at mRNA and protein level was ascertained. In the case of 10 patients (62.5%), higher p53 gene expression at mRNA level was observed, whereas higher level of P53 protein was determined only in four subjects (25%). In two of 16 cases (12.5%), protein product of bcl-2 gene was found, while in eight subjects (50%)--mRNA expression of the gene.


Subject(s)
Biomarkers, Tumor/analysis , Carcinoma, Non-Small-Cell Lung/chemistry , Lung Neoplasms/chemistry , Proto-Oncogene Proteins c-bcl-2/analysis , Tumor Suppressor Protein p53/analysis , Adult , Aged , Biomarkers, Tumor/genetics , Female , Gene Expression Regulation, Neoplastic , Humans , Immunohistochemistry , In Situ Hybridization , Male , Middle Aged , Neoplasm Staging , Proto-Oncogene Proteins c-bcl-2/genetics , RNA, Messenger/analysis , Tumor Suppressor Protein p53/genetics , bcl-X Protein
13.
Pneumonol Alergol Pol ; 70(1-2): 34-43, 2002.
Article in Polish | MEDLINE | ID: mdl-12148174

ABSTRACT

The aim of the study is the assessment of efficacy of combined treatment (preoperative chemotherapy and surgery) of locally advanced non-small cell lung cancer. Material included sixty-two NSCLC patients treated in the Department of Thoracic Surgery of Medical School of Lublin between February 1993 and October 1997. Treatment was started with 2 or 3 courses of chemotherapy. In 51 cases chemotherapy was based on Cisplatin. Response (CR + PR) to chemotherapy was observed in 30 cases (48.8%). 21-25 days after last course of chemotherapy resections were carried out. In 1 case it was lobectomy, in 25 cases--pneumonectomy and in 36--extended pneumonectomy. In 56 cases resection was radical, in 6 cases non-radical. No perioperative deaths or bronchial fistulas were observed. Median survival was 21.4 months and 5-years survival--35.25%. The results confirm the usefulness of preoperative chemotherapy in locally advanced NSCLC.


Subject(s)
Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Carcinoma, Non-Small-Cell Lung/drug therapy , Carcinoma, Non-Small-Cell Lung/surgery , Lung Neoplasms/drug therapy , Lung Neoplasms/surgery , Adult , Aged , Female , Humans , Male , Middle Aged , Neoadjuvant Therapy , Preoperative Care/methods , Remission Induction , Retrospective Studies , Survival Rate , Time Factors
14.
Biochem Pharmacol ; 63(4): 625-34, 2002 Feb 15.
Article in English | MEDLINE | ID: mdl-11992630

ABSTRACT

Recently, accumulated statistical data indicate the protective effect of caffeine consumption against several types of cancer diseases. There are also reports about protective effect of caffeine and other xanthines against tumors induced by polycyclic aromatic hydrocarbons. One of the explanations is based on biological activation of such carcinogens by cytochromes that are also known for metabolism of caffeine. However, there is also numerous data indicating reverse effect on cytotoxicity of anticancer drugs that inhibit the action of topoisomerase I (e.g. Camptothecin or Topotecan) and topoisomerase II inhibitors (e.g. Doxorubicin, Mitoxantrone or mAMSA). In this work we tested the hypothesis that the caffeine protective effect is the result of sequestering of aromatic mutagens by formation of stacking (pi-pi) complexes. As the models for the study we have chosen two well-known mutagens, that do not require metabolical activation: quinacrine mustard(QM, aromatic, heterocyclic nitrogen mustard) and mechlorethamine (NM2, aliphatic nitrogen mustard). The flow cytometry study of these agents' action on the cell cycle of HL-60 cells indicated that caffeine prevents the cytotoxic action of QM, but not that of NM2. The formations of stacking complexes of QM with caffeine were confirmed by light absorption, calorimetric measurements and by molecular modeling calculation. Using the statistical thermodynamics calculations we calculated the "neighborhood" association constant (K(AC)=59+/-2M(-1)) and enthalpy change (DeltaH(0')=-116cal mol(-1)); the favorable entropy change of complex formation (DeltaS(0')=7.72cal mol(-1)K(-1), due to release of several water molecules, associated with components in the process of complex formation). The Gibbs' free energy change of QM-CAF formation is DeltaG(0')=-2.41kcal mol(-1). We were unable to detect any interaction between NM2 and caffeine either by spectroscopic or calorimetric measurement. In order to establish, whether the intercalation of QM plays any role in cytotoxic effect we tested, as a control, non-alkylatiatig, but also intercalating QM derivative-quinacrine (Q). The later had no cytostatic effect on HL-60 cell even at there order of higher concentration than QM or NM2 but, similar to QM forms (which we demonstrated) stacking complexes with caffeine (K(AC)=75+/-3M(-1)). These results strongly indicate, that the attenuating effect of caffeine on cytotoxic or mutagenic effects of some mutagens, is not the results of metabolic processes in the cells, but simply the physicochemical process of sequestering of aromatic molecules (potential carcinogens or mutagens) by formation of stacking complexes with them. The caffeine may then act as the "interceptor" of potential carcinogens (especially in the upper part of digesting track where its concentration can reach the concentration of mM level). There is, however, no indication either in the literature or in our experiments that xanthines can reverse the damage to nucleic acids when the damage to DNA has already occurred.


Subject(s)
Antineoplastic Agents/pharmacology , Caffeine/pharmacology , DNA Damage , Quinacrine Mustard/pharmacology , Xanthines/pharmacology , Calorimetry , Cell Cycle/drug effects , Cell Division/drug effects , DNA/drug effects , DNA/metabolism , Drug Interactions , HL-60 Cells , Humans , Models, Molecular , Quinacrine/pharmacology , Spectrophotometry, Atomic , Titrimetry , Tumor Cells, Cultured
15.
Biochem Pharmacol ; 63(4): 635-46, 2002 Feb 15.
Article in English | MEDLINE | ID: mdl-11992631

ABSTRACT

Recently accumulated statistical data indicate the protective effect of caffeine consumption against several types of cancer diseases. There are also reports about protective effect of caffeine and other xanthines against tumors induced by polycyclic aromatic hydrocarbons. One of the explanations of this phenomenon is based on biological activation of such carcinogens by cytochromes that are also known for metabolism of caffeine. In the accompanying paper [Kapuscinski et al., this issue] we provide evidence (flow cytometry and the cell cycle analysis) that the cytostatic effects of caffeine (CAF) on two DNA alkylating agents, which do not require the biological activation, depend on their ability to form stacking (pi-pi) complexes. In this study, we use physicochemical techniques (computer aided light absorption and microcalorimetry), and molecular modeling to examine previously published qualitative data. This is published both by our and other group's data, indicates that CAF is able to modify the cytotoxic and/or cytostatic action of the two well known antitumor drugs doxorubicin (DOX) and mitoxantrone (MIT). To obtain the quantitative results from the experimental data we used the statistical-thermodynamical model of mixed aggregation, to find the association constants K(AC) of the CAF-drug interaction (128+/-10 and 356+/-21M(-1) for DOX-CAF and MIT-CAF complex formation, respectively). In addition, the favorable enthalpy change of CAF-MIT (DeltaH=-11.3kcal/mol) was measured by microcalorimetry titration. The molecular modeling (semi-empirical and force field method) allowed us to obtain the geometry of these complexes, which indicated the favorable energy (DeltaE) of complex formation of the protonated drug's molecules in aqueous environment (-7.4 and -8.7kcal/mol for DOX-CAF.5H(2)O and MIT-CAF.8H(2)O complex, respectively). The molecular modeling calculation indicates the existence of CAF-drug complexes in which the MIT molecules are intercalated between two CAF molecules (DeltaE=-29.9kcal/mol). These results indicate that the attenuating effect of caffeine on cytotoxic or mutagenic effects of some polycyclic aromatic mutagens cannot be the result of metabolic activation in the cells, but simply is the physicochemical process of the sequestering of aromatic molecules (e.g. carcinogens or mutagens) by formation of the stacking complexes. The caffeine may then act as the "interceptor" of potential carcinogens (especially in the upper part of digesting track) where its concentration can reach the mM level). There is, however, no indication, both, in the literature or from our experiments, that the xanthines can reverse the damage to nucleic acids at the point when the damage to DNA has already occurred.


Subject(s)
Antineoplastic Agents/chemistry , Caffeine/chemistry , DNA Damage , Doxorubicin/chemistry , Mitoxantrone/chemistry , Xanthines/chemistry , Calorimetry , DNA/drug effects , DNA/metabolism , Dimerization , Drug Interactions , Humans , Models, Molecular , Polycyclic Aromatic Hydrocarbons/chemistry , Spectrophotometry, Atomic , Titrimetry , Tumor Cells, Cultured
SELECTION OF CITATIONS
SEARCH DETAIL
...